Focal Segmental Glomerulosclerosis Recurrence in the Renal Allograft

Advances in Chronic Kidney Disease

Volumn 21, Issue 5, 2014, Pages 448-452

  Leca, Nicolae ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

FSGS; Kidney transplantation; Proteinuria; Recurrent disease; Renal allograft

Indexed keywords

ALLOGRAFT; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMAN; KIDNEY; KIDNEY TRANSPLANTATION; PATHOLOGY; RECURRENT DISEASE;

ALLOGRAFTS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; RECURRENCE;

EID: 84906734388     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.06.004     Document Type: Review

References (49)

1. Kitiyakara C., Eggers P., Kopp J.B. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 2004, 44(5):815-825.
2. Hickson L.J., Gera M., Amer H., et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009, 87(8):1232-1239.
3. Vinai M., Waber P., Seikaly M.G. Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review. Pediatr Transplant 2010, 14(3):314-325.
4. Pardon A., Audard V., Caillard S., et al. Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. Nephrol Dial Transplant 2006, 21(4):1053-1059.
5. Ponticelli C., Glassock R.J. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol 2010, 5(12):2363-2372.
6. Shimizu A., Higo S., Fujita E., Mii A., Kaneko T. Focal segmental glomerulosclerosis after renal transplantation. Clin Transplant 2011, 25(Suppl 23):6-14.
7. Sener A., Bella A.J., Nguan C., Luke P.P., House A.A. Focal segmental glomerular sclerosis in renal transplant recipients: predicting early disease recurrence may prolong allograft function. Clin Transplant 2009, 23(1):96-100.
8. Baum M.A. Outcomes after renal transplantation for FSGS in children. Pediatr Transplant 2004, 8(4):329-333.
9. Couser W. Recurrent glomerulonephritis in the renal allograft: an update of selected areas. Exp Clin Transplant 2005, 3(1):283-288.
10. Weber S., Tönshoff B. Recurrence of focal-segmental glomerulosclerosis in children after renal transplantation: clinical and genetic aspects. Transplantation 2005, 80(suppl 1):S128-134.
11. IJpelaar D.H., Farris A.B., Goemaere N., et al. Fidelity and evolution of recurrent FSGS in renal allografts. J Am Soc Nephrol 2008, 19(11):2219-2224.
12. Canaud G., Dion D., Zuber J., et al. Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant 2010, 25(4):1321-1328.
13. Swaminathan S., Lager D.J., Qian X., Stegall M.D., Larson T.S., Griffin M.D. Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants. Nephrol Dial Transplant 2006, 21(9). 2607-2314.
14. D'Agati V.D., Kaskel F.J., Falk R.J. Focal segmental glomerulosclerosis. N Engl J Med 2011, 365(25):2398.
15. Chang J.W., Pardo V., Sageshima J., et al. Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosis. Transplantation 2012, 93(12):1238-1244.
16. Savin V.J., Sharma R., Sharma M., et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996, 334(14):878-883.
17. Wei C., El Hindi S., Li J., et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011, 17(8):952-960.
18. Alachkar N., Wei C., Arend L.J., et al. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation 2013, 96(7):649-656.
19. Franco Palacios C.R., Lieske J.C., Wadei H.M., et al. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 2013, 96(4):394-399.
20. Bock M.E., Price H.E., Gallon L., Langman C.B. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol 2013, 8(8):1304-1311.
21. Sever S., Trachtman H., Wei C., Reiser J. Is there clinical value in measuring suPAR levels in FSGS?. Clin J Am Soc Nephrol 2013, 8(8):1273-1275.
22. Jefferson J.A., Shankland S.J. Has the circulating permeability factor in primary FSGS been found?. Kidney Int 2013, 84(2):235-238.
23. McCarthy E.T., Sharma M., Savin V.J. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010, 5(11):2115-2121.
24. Alachkar N., Gupta G., Montgomery R.A. Angiotensin antibodies and focal segmental glomerulosclerosis. N Engl J Med 2013, 368(10):971-973.
25. Lopez-Hellin J., Cantarell C., Jimeno L., et al. A form of apolipoprotein a-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantation. Am J Transplant 2013, 13(2):493-500.
26. Bertelli R., Ginevri F., Caridi G., et al. Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis 2003, 41(6):1314-1321.
27. Becker-Cohen R., Bruschi M., Rinat C., et al. Recurrent nephrotic syndrome in homozygous truncating NPHS2 mutation is not due to anti-podocin antibodies. Am J Transplant 2007, 7(1):256-260.
28. Jungraithmayr T.C., Hofer K., Cochat P., et al. Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation. J Am Soc Nephrol 2011, 22(3):579-585.
29. Bouchireb K., Boyer O., Gribouval O., et al. NPHS2 mutations in steroid-resistant nephrotic syndrome: a mutation update and the associated phenotypic spectrum. Hum Mutat 2014, 35(2):178-186.
30. Weber S., Gribouval O., Esquivel E.L., et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 2004, 66(2):571-579.
31. Kopp J.B., Smith M.W., Nelson G.W., et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40(10):1175-1184.
32. Pollak M.R. Kidney disease and African ancestry. Nat Genet 2008, 40(10):1145-1146.
33. Friedman D.J., Kozlitina J., Genovese G., Jog P., Pollak M.R. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol 2011, 22(11):2098-2105.
34. Ali A.A., Wilson E., Moorhead J.F., et al. Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment?. Transplantation 1994, 58(7):849-852.
35. Gallon L., Leventhal J., Skaro A., Kanwar Y., Alvarado A. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med 2012, 366(17):1648-1649.
36. Wei C., Möller C.C., Altintas M.M., et al. Modification of kidney barrier function by the urokinase receptor. Nat Med 2008, 14(1):55-63.
37. Kowalewska J. Pathology of recurrent diseases in kidney allografts: membranous nephropathy and focal segmental glomerulosclerosis. Curr Opin Organ Transplant 2013, 18(3):313-318.
38. Pippin J.W., Sparks M.A., Glenn S.T., et al. Cells of renin lineage are progenitors of podocytes and parietal epithelial cells in experimental glomerular disease. Am J Pathol 2013, 183(2):542-557.
39. Fatima H., Moeller M.J., Smeets B., et al. Parietal epithelial cell activation marker in early recurrence of FSGS in the transplant. Clin J Am Soc Nephrol 2012, 7(11):1852-1858.
40. Cravedi P., Kopp J.B., Remuzzi G. Recent progress in the pathophysiology and treatment of FSGS recurrence. Am J Transplant 2013, 13(2):266-274.
41. Beaudreuil S., Zhang X., Kriaa F., et al. Protein A immunoadsorption cannot significantly remove the soluble receptor of urokinase from sera of patients with recurrent focal segmental glomerulosclerosis. Nephrol Dial Transplant 2014, 29(2):458-463.
42. Fornoni A., Sageshima J., Wei C., et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011, 3(85):85ra46.
43. Araya C.E., Dharnidharka V.R. The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review. J Transplant 2011, 2011:374213.
44. Tsagalis G., Psimenou E., Nakopoulou L., Laggouranis A. Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation. Artif Organs 2011, 35(4):420-425.
45. Leroy S., Guigonis V., Bruckner D., et al. Successful anti-TNFalpha treatment in a child with posttransplant recurrent focal segmental glomerulosclerosis. Am J Transplant 2009, 9(4):858-861.
46. Yu C.C., Fornoni A., Weins A., et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013, 369(25):2416-2423.
47. Hariharan S., Adams M.B., Brennan D.C., et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 1999, 68(5):635-641.
48. Briganti E.M., Russ G.R., McNeil J.J., Atkins R.C., Chadban S.J. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002, 347(2):103-109.
49. Abbott K.C., Sawyers E.S., Oliver J.D., et al. Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States. Am J Kidney Dis 2001, 37(2):366-373.